Filtered By:
Specialty: Drugs & Pharmacology
Condition: Thrombosis
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 546 results found since Jan 2013.
Do novel oral anticoagulant drugs used in patients with nonvalvular atrial fibrillation act only as anticoagulants?
CONCLUSIONS: The results indicated that the NOAC used in anticoagulation treatment do not only act as anticoagulants but also reduce inflammation and platelet reactivation, which have an important role in the pathogenesis of AF and thromboembolism.PMID:37070895 | DOI:10.26355/eurrev_202304_31926
Source: European Review for Medical and Pharmacological Sciences - April 18, 2023 Category: Drugs & Pharmacology Authors: T Çakmak E Çakmak F Balgetir E Ya şar Y Karaku ş Source Type: research
Neutrophil Extracellular Traps in Cerebral Ischemia/Reperfusion Injury: Friend and Foe
Curr Neuropharmacol. 2023 Mar 8. doi: 10.2174/1570159X21666230308090351. Online ahead of print.ABSTRACTCerebral ischemic injury, one of the leading causes of morbidity and mortality worldwide, triggers various central nervous system (CNS) diseases, including acute ischemic stroke (AIS) and chronic ischemia-induced Alzheimer's disease (AD). Currently, targeted therapies are urgently needed to address neurological disorders caused by cerebral ischemia/reperfusion injury (CI/RI), and the emergence of Neutrophil extracellular traps (NETs) may be able to relieve the pressure. Neutrophils are precursors to brain injury following...
Source: Current Neuropharmacology - March 9, 2023 Category: Drugs & Pharmacology Authors: Haoyue Luo Hanjing Guo Yue Zhou Rui Fang Wenli Zhang Zhigang Mei Source Type: research
Choice and Timing of Antithrombotic After Ischemic Stroke, Intracerebral Hemorrhage or Cerebral Venous Thrombosis
CNS Neurol Disord Drug Targets. 2023 Mar 9. doi: 10.2174/1871527322666230309100626. Online ahead of print.ABSTRACTStroke is a multifactorial vascular disease and remains a leading cause of disability in the United States. Strokes can be ischemic or hemorrhagic in nature and secondary to arterial or venous disease, making determining the etiology and secondary prevention strategy important for preservation of the injured brain, prevention of recurrent strokes, and in the maintenance of good functional outcomes for patients impacted by stroke. In this narrative review, we provide a synopsis of the available medical evidence ...
Source: CNS and Neurological Disorders Drug Targets - March 9, 2023 Category: Drugs & Pharmacology Authors: Dylan Ryan Tarun Girotra Wuwei Feng Source Type: research
Neutrophil Extracellular Traps in Cerebral Ischemia/Reperfusion Injury: Friend and Foe
Curr Neuropharmacol. 2023 Mar 8. doi: 10.2174/1570159X21666230308090351. Online ahead of print.ABSTRACTCerebral ischemic injury, one of the leading causes of morbidity and mortality worldwide, triggers various central nervous system (CNS) diseases, including acute ischemic stroke (AIS) and chronic ischemia-induced Alzheimer's disease (AD). Currently, targeted therapies are urgently needed to address neurological disorders caused by cerebral ischemia/reperfusion injury (CI/RI), and the emergence of Neutrophil extracellular traps (NETs) may be able to relieve the pressure. Neutrophils are precursors to brain injury following...
Source: Current Neuropharmacology - March 9, 2023 Category: Drugs & Pharmacology Authors: Haoyue Luo Hanjing Guo Yue Zhou Rui Fang Wenli Zhang Zhigang Mei Source Type: research
Choice and Timing of Antithrombotic After Ischemic Stroke, Intracerebral Hemorrhage or Cerebral Venous Thrombosis
CNS Neurol Disord Drug Targets. 2023 Mar 9. doi: 10.2174/1871527322666230309100626. Online ahead of print.ABSTRACTStroke is a multifactorial vascular disease and remains a leading cause of disability in the United States. Strokes can be ischemic or hemorrhagic in nature and secondary to arterial or venous disease, making determining the etiology and secondary prevention strategy important for preservation of the injured brain, prevention of recurrent strokes, and in the maintenance of good functional outcomes for patients impacted by stroke. In this narrative review, we provide a synopsis of the available medical evidence ...
Source: CNS and Neurological Disorders Drug Targets - March 9, 2023 Category: Drugs & Pharmacology Authors: Dylan Ryan Tarun Girotra Wuwei Feng Source Type: research
Neutrophil Extracellular Traps in Cerebral Ischemia/Reperfusion Injury: Friend and Foe
Curr Neuropharmacol. 2023 Mar 8. doi: 10.2174/1570159X21666230308090351. Online ahead of print.ABSTRACTCerebral ischemic injury, one of the leading causes of morbidity and mortality worldwide, triggers various central nervous system (CNS) diseases, including acute ischemic stroke (AIS) and chronic ischemia-induced Alzheimer's disease (AD). Currently, targeted therapies are urgently needed to address neurological disorders caused by cerebral ischemia/reperfusion injury (CI/RI), and the emergence of Neutrophil extracellular traps (NETs) may be able to relieve the pressure. Neutrophils are precursors to brain injury following...
Source: Current Neuropharmacology - March 9, 2023 Category: Drugs & Pharmacology Authors: Haoyue Luo Hanjing Guo Yue Zhou Rui Fang Wenli Zhang Zhigang Mei Source Type: research
Choice and Timing of Antithrombotic After Ischemic Stroke, Intracerebral Hemorrhage or Cerebral Venous Thrombosis
CNS Neurol Disord Drug Targets. 2023 Mar 9. doi: 10.2174/1871527322666230309100626. Online ahead of print.ABSTRACTStroke is a multifactorial vascular disease and remains a leading cause of disability in the United States. Strokes can be ischemic or hemorrhagic in nature and secondary to arterial or venous disease, making determining the etiology and secondary prevention strategy important for preservation of the injured brain, prevention of recurrent strokes, and in the maintenance of good functional outcomes for patients impacted by stroke. In this narrative review, we provide a synopsis of the available medical evidence ...
Source: CNS and Neurological Disorders Drug Targets - March 9, 2023 Category: Drugs & Pharmacology Authors: Dylan Ryan Tarun Girotra Wuwei Feng Source Type: research
Neutrophil Extracellular Traps in Cerebral Ischemia/Reperfusion Injury: Friend and Foe
Curr Neuropharmacol. 2023 Mar 8. doi: 10.2174/1570159X21666230308090351. Online ahead of print.ABSTRACTCerebral ischemic injury, one of the leading causes of morbidity and mortality worldwide, triggers various central nervous system (CNS) diseases, including acute ischemic stroke (AIS) and chronic ischemia-induced Alzheimer's disease (AD). Currently, targeted therapies are urgently needed to address neurological disorders caused by cerebral ischemia/reperfusion injury (CI/RI), and the emergence of Neutrophil extracellular traps (NETs) may be able to relieve the pressure. Neutrophils are precursors to brain injury following...
Source: Current Neuropharmacology - March 9, 2023 Category: Drugs & Pharmacology Authors: Haoyue Luo Hanjing Guo Yue Zhou Rui Fang Wenli Zhang Zhigang Mei Source Type: research
Utilization of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
ConclusionsThe utilization of TAT following PCI among high-stroke risk AF patients steadily increased from 2011 to 2020, reaching 65.4% by the end of the study period. However, in 2020, a significant proportion of 29.4% of patients still received DAPT, indicating that many AF patients undergoing PCI did not receive adequate antithrombotic therapy.
Source: European Journal of Clinical Pharmacology - February 24, 2023 Category: Drugs & Pharmacology Source Type: research
